Capital is rotating from memory stocks into hyperscalers amid fears of a cyclical peak and Korean ETF regulations. AI hardware spending is cannibalizing legacy IT, evidenced by IBM's severe miss. ASTS faces intense backlash over a surprise $1B dilution, while Nebius is praised for an asset-light data center pivot.
Institutional capital is rotating out of memory and semiconductor equipment into large-cap hyperscalers. Bears cite decelerating DRAM price growth, institutional rebalancing, and South Korean regulatory intervention targeting leveraged ETFs tied to SK Hynix and Samsung. Bulls argue the selloff has cleared excess leverage, presenting a deep-value entry point.
IBM suffered its worst single-day drop since 1987 following a severe revenue miss. Management and analysts confirm that enterprise clients are deferring traditional software and mainframe upgrades to fund AI hardware and cybersecurity initiatives.
AST SpaceMobile announced a $1B convertible note offering immediately after market close, contradicting prior management assurances that the company was fully funded for 2026. The move triggered intense retail anger, accusations of a pump-and-dump, and renewed conviction from short sellers.
Nebius Group introduced a franchise-style expansion model where infrastructure partners fund data center construction while Nebius provides the software architecture and sales. This removes the primary capital constraint to growth and prevents shareholder dilution.
Traders are accumulating specific AI infrastructure names with tangible capacity constraints or capital-light models, such as NBIS and AAOI, while fading broader semiconductor indices.
Market participants are initiating long positions in BTC, ETH, and perp DEX tokens, citing seller exhaustion and a rotation out of tech momentum.
Value-oriented traders are waiting for specific support levels (e.g., $700-$850 for MU) or selling out-of-the-money puts to acquire shares at a discount, demanding technical stabilization first.
High-multiple fab equipment stocks are being faded due to parabolic price moves and extreme earnings expectations, despite ASML's recent guidance raise.
Investors are actively shorting or avoiding ASTS and CRML due to sudden dilution, high capital intensity, and perceived low business quality.